Moleculin Biotech, Inc. (MBRX) vs Onconetix, Inc. (ONCO)
A side-by-side comparison of Moleculin Biotech, Inc. and Onconetix, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MBRX
Moleculin Biotech, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 11:32 AM EDT
ONCO
Onconetix, Inc.
$0.65HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Total return — MBRX vs ONCO
growth of $100 · dividends reinvested · last 5yMBRX -99.9% (-75.2%/yr)ONCO -100.0% (-96.3%/yr)MBRX compounded faster over this window
Log scale — wide-divergence pair
MBRX ONCO
MBRX vs ONCO: by the numbers
- •MBRX is the larger company ($2M vs $2M market cap).
- •Both run net losses; MBRX's is the smaller (0.00% vs -1578.79% net margin).
Metrics side by side
Valuation
| Metric | MBRX | ONCO |
|---|---|---|
| P/S ratio | N/A | 3.61 |
| P/B ratio | 0.21 | 0.17 |
Profitability
| Metric | MBRX | ONCO |
|---|---|---|
| Gross margin | 0.00% | 80.40% |
| Operating margin | 0.00% | -778.16% |
| Net margin | 0.00% | -1578.79% |
| ROE | -261.73% | -75.70% |
| ROIC | -242.25% | -59.84% |
Growth (annualized)
| Metric | MBRX | ONCO |
|---|---|---|
| Total return CAGR (5Y) | -78.48% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.